LIMN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Liminatus Pharma Inc (LIMN) is not a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The stock lacks positive momentum, has no significant trading signals, and its financial performance is weak with negative income and EPS. Additionally, there are no positive catalysts or recent news to support a bullish outlook.
The MACD is positive and expanding, indicating some bullish momentum. However, the RSI is neutral at 67.118, and the moving averages are bearish (SMA_200 > SMA_20 > SMA_5). The stock is currently trading near its resistance levels (R1: 0.203, R2: 0.215), suggesting limited upside potential in the short term.
NULL identified. No recent news or events to act as a positive catalyst.
The stock is projected to decline in the next day (-0.59%), week (-3.22%), and month (-6.08%). Financial performance is poor, with negative income and EPS. No significant insider or hedge fund activity.
In Q4 2025, the company reported zero revenue growth (0.00% YoY), a net income of -$8,168,927 (up 3467.22% YoY), and an EPS of -0.48 (up 4700.00% YoY). Despite the improvement in percentages, the company remains unprofitable with no revenue or gross margin.
No analyst rating or price target data available.
